|Chemical and physical data|
|Molar mass||371.231 g/mol g·mol−1|
|3D model (JSmol)|
Remeglurant (INN; developmental code name MRZ-8456) is a drug which acts as a selective antagonist of the mGlu5 receptor. It is under development by Merz Pharmaceuticals for the treatment of drug-induced dyskinesia but no development has been reported since at least 2016.
- World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN): Proposed INN: List 109" (PDF). WHO Drug Information. World Health Organization. 27 (2).
- Danysz W, et al. Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators. US Patent 7985753, 4 August 2006.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|